That is not quite right. Our vaccine trial was for resected melanoma, stage 3 and 4” the primary end point was disease recurrence.
We had an 80% reduction in recurrence over 2 yrs for stage 4” 100% of the control recurred. Similar results are expected for stage 3 patients at 3 yrs,
A trial in metestatic patients in combination with checkpoint therapy is also underway. Disease progression are the endpoints in that trial.